Acorai – redefining remote heart failure management

Acorai is developing a non-invasive intracardiac pressure monitoring tool to help reduce heart failure (HF) re-hospitalizations. We are applying machine learning methods to non-invasively estimate intracardiac pressure of the heart in order to identify impending HF and be able to reduce HF re-hospitalizations. Our product easily connects to a smartphone, enabling a home-use test that can be carried out by anyone, anywhere, in under just a couple of minutes per day.

50% of HF patients require readmission within 6 months, 75% of which may be preventable. However, existing intracardiac pressure monitoring (ICPM) tools are both invasive, expensive and fail to identify impending HF in 50% of cases. In fact, despite medical advances, HF hospitalisations are growing rapidly with a substantial clinical and financial burden to society.

Acorai is redefining remote HF management by enabling non-invasive ICPM to help reduce HF re-hospitalizations. Acorai's AI-engine enables personalized treatment and is automatically adapted and calibrated to the patient's heart. The AI is able to identify very early indications of heart changes and elevated pressure (which often precedes HF) of which the patient’s cardiologist is notified so that timely precautionary measures can be taken. A smart connected healthcare solution, using AI where humans would not suffice.

Acorai’s product is an extended smartphone case with a unique combination of sensors configured to enhance low-frequency sound and seismic signals pertaining to intracardiac pressure. The product is intended for daily home use where the patient places the smartphone case against his or her chest for a couple of minutes each day. It can drastically free up resources during patient monitoring to reduce emergency HF visits. The product has been validated in several laboratory experiments and is undergoing its first clinical trial with 700+ HF patients in 2021Q2. Acorai is looking to submit its FDA application by 2022Q1.

Today, the most commonly used method for recurring HF is to monitor physical symptoms like increased weight and breathing difficulties. Many patients are brought in for check-ups once or twice a year in order to study intracardiac pressure through an invasive heart catheterization, which is both expensive and unpleasant. Acorai’s product not only has the potential of earlier detection of impending heart failure, but its affordability and ease of use will help relieve pressure on an increasingly strained healthcare system.

A truly innovative breakthrough in modern medical technology.